21 Aug 2025 by admin in UncategorizedComments Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
08 Jul 2025 by admin in UncategorizedComments U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC for Gastric Cancer
08 Jul 2025 by admin in UncategorizedComments Avenzo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate
30 Jun 2025 by admin in UncategorizedComments Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
26 Jun 2025 by admin in UncategorizedComments Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia
16 Jun 2025 by admin in UncategorizedComments NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
11 Jun 2025 by admin in UncategorizedComments Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
21 Apr 2025 by admin in UncategorizedComments Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
17 Apr 2025 by admin in UncategorizedComments Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
